Skip to main content
Cancer Medicine logoLink to Cancer Medicine
. 2014 Jul 24;3(6):1539–1543. doi: 10.1002/cam4.308

Outpatient treatment costs and their potential impact on cancer care

Takahiro Isshiki 1
PMCID: PMC4298380  PMID: 25060622

Abstract

Cancer creates a tremendous financial burden. Cancer-related costs are categorized into direct, indirect, and psychosocial costs. Although there have been many reports on medical care costs, which are direct, those on other costs are extremely scarce. We estimated travel time and costs required for cancer patients to receive outpatient treatment. We studied 521 cancer patients receiving anti-cancer treatment between February 2009 and December 2012 at the Outpatient Chemotherapy Center of Teikyo University Chiba Medical Center. Address data were extracted from Data Warehouse electronic medical records, and travel distance and time required for outpatient treatment were calculated via MapInfo and ACT Distance Calculator Package. Transportation costs were estimated on the basis of ¥274 (=$3.00) per kilometer. The study design was approved by an ethics review board of Teikyo University (12–851). Average round-trip travel distance, time, and cost for all patients were 26.7 km, 72.5 min, and ¥7,303 ($79.99), respectively. Cancer patients incurred a travel cost of ¥4000–¥9000 ($40.00 to $100.00) for each outpatient treatment. With population aging, seniors living alone and senior households are increasing, and outpatient visits are becoming a common burden.

Keywords: Cancer, cost, electronic medical record data, outpatient treatment, time

Introduction

Cancer creates a tremendous financial burden [1]. Cancer-related costs are categorized into direct, indirect, and psychosocial costs. Although many reports are available on medical care costs, which are direct, those on other costs are extremely scarce [2]. We estimated travel time and costs required for cancer patients to receive outpatient treatment.

Methods

We studied 521 cancer patients receiving anti-cancer treatment between February 2009 and December 2012 at the Outpatient Chemotherapy Center of Teikyo University Chiba Medical Center. Address data were extracted from Data Warehouse electronic medical records. Travel distance and time required for outpatient treatment were calculated via software MapInfo® (Pitney Bowes Software K.K., Tokyo, Japan) and ACT Distance Calculator Package® (Advanced Core Technologies, Inc., Tokyo, Japan). Transportation costs were estimated on the basis of ¥274 (=$3.00) per kilometer (http://www.civil.eng.osaka-u.ac.jp/plan/staff/inoi/keikaku08_3.pdf). The study design was approved by an ethics review board of Teikyo University (12–851). Address data were anonymized and de-identified prior to analysis.

Results

The maps display the address points of patients by cancer type (Figs. 15). Average round-trip travel distances, times, and costs by cancer type are shown in the Table 1. Average round-trip travel distance, time, and cost for all patients were 26.7 km, 72.5 min, and $79.99, respectively.

Figure 1.

Figure 1

Address points of stomach (orange), liver (green) cancer patients, and the hospital (red).

Figure 5.

Figure 5

Address points of malignant lymphoma (olive), multiple myeloma (light blue) patients, and the hospital (red).

Table 1.

Average round-trip travel distances, times, and costs by cancer type.

Cancer site Stomach (n = 47) Liver (n = 15) Pancreas (n = 25) Uterus (n = 55) Breast (n = 86) Prostate (n = 51) Colon (n = 123) Lung (n = 49) Malignant lymphoma (n = 55) Multiple myeloma (n = 15)
Age (range/median) 68.8 (39–87/69) 66.7 (56–81/66) 67.1 (39–83/68) 57.2 (24–80/59) 57.3 (33–84/57) 71.6 (39–89/72) 63.3 (33–83/63) 66.7 (36–82/70) 61.0 (5–84/65) 66.9 (48–81/63)
Distance (km) (range/median) 19.4 (2.2–82.0/12) 31.4 (4.2–75.2/25.2) 1.4 (2.0–60.2/13.0) 24.6 (2.4–71.4/16.8) 22.5 (0.8–117.6/15.9) 31.6 (0–94.2/24.0) 29.5 (0.4–165.4/18.8) 27.1 (1.0–142.0/17.6) 33.7 (1.4–99.6/23.8) 28.6 (0.4–98.6/18.8)
Time (min) (range/median) 54.7 (10–160/42) 87.1 (18–154/82) 47.6 (8–140/46) 70.0 (10–166/56) 63.2 (4–238/52) 83.4 (0–182/66) 77.3 (2–296/62) 74.3 (4–342/60) 88.1 (6–230/72) 77.9 (2–232/62)
Cost ($) (range/median) 58.1 (6.6–246.1/36.0) 94.4 (12.6–225.7/75.6) 43.3 (6.0–180.7/39.0) 73.9 (7.2–214.3/50.4) 67.6 (2.4–352.9/47.7) 94.7 (0–282.7/72.0) 88.7 (1.2–496.4/56.4) 81.2 (3.0–426.2/52.8) 101.2 (4.2–298.9/71.4) 85.7 (1.2–295.9/56.4)

Figure 2.

Figure 2

Address points of lung (yellow), colon (blue) cancer patients, and the hospital (red).

Figure 3.

Figure 3

Address points of pancreas (light green), uterine (purple) cancer patients, and the hospital (red).

Figure 4.

Figure 4

Address points of breast (pink), prostate (brown) cancer patients, and the hospital (red).

Discussion

Moore reported that out-of-pocket costs (including transportation fee, over-the-counter medications, and insurance premiums) about $360 per month [3]. We estimated that travel cost, which accounts for a significant part of out-of-pocket costs, is $40–$100.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) altered the guidelines for reimbursements for outpatient chemotherapy drugs and drug administration services in the United States. Friedman et al. reported that access to care between pre-MMA and post-MMA patients has no statistically significant difference [4]. Shea et al. also reported that median travel distance for chemotherapy is 11.2–12.8 km. Travel distance for chemotherapy in the Medicare population has not seen major changes after the enactment of the MMA [5].

Limitation

As this study was performed only in a single facility, a meaningful tendency in travel time and costs was not seen in relation to the number of patients and specialists for each cancer type. A study in multiple facilities may show a notable trend.

Conclusions

Cancer patients incurred a travel time of 45–90 min and a cost of $40–$100 for each outpatient treatment. Cancer patients carry rising burdens of health care-related out-of-pocket expenses. With population aging, seniors living alone, and increasing number of senior households, outpatient visits are becoming a common burden.

Acknowledgments

Financial support for this study was provided by the Clinical Cancer Research, Health and Labor Sciences Research Grants (No. 13801816), Ministry of Health, Labor and Welfare, Tokyo, Japan.

Conflict of Interest

None declared.

References

  • 1.wGuy GP, Jr, Yabroff KR, Ekwueme DU, Smith AW, Dowling EC, Rechis R, et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff. 2014;33:1024–1031. doi: 10.1377/hlthaff.2013.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ekwueme DU, Yabroff KR, Guy GP, Jr, Banegas MP, Moor JS, de, Li C, et al. Medical costs and productivity losses of cancer survivors – United States, 2008–2011. Morb. Mortal. Wkly. Rep. 2014;63:505–510. [PMC free article] [PubMed] [Google Scholar]
  • 3.Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs. 1999;22:389–396. doi: 10.1097/00002820-199910000-00007. [DOI] [PubMed] [Google Scholar]
  • 4.Friedman JY, Curtis LH, Hammill BG, Dhillon JK, Weaver CH, Biswas S, et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care? Cancer. 2007;110:2304–2312. doi: 10.1002/cncr.23042. [DOI] [PubMed] [Google Scholar]
  • 5.Shea AM, Curtis LH, Hammill BG, DiMartino LD, Abernethy AP. Schulman KA. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA. 2008;300:189–196. doi: 10.1001/jama.300.2.189. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Medicine are provided here courtesy of Wiley

RESOURCES